Brickell Biotech Doses First Patient in Second U.S. Pivotal Phase 3 Clinical Study
Topline results from the U.S. pivotal Phase 3 program anticipated in the fourth quarter of 2021 Sofpironium bromide gel, 5%
Read moreUS10802T1051
Brickell Biotech Announces Launch Date for Sofpironium Bromide Gel, 5% (ECCLOCK®) in Japan by its Development Partner, Kaken Pharmaceutical
Kaken plans to launch ECCLOCK® for the treatment of primary axillary hyperhidrosis in Japan on November 26, 2020– – –ECCLOCK®
Read moreBrickell Biotech to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on November 12, 2020
BOULDER, Colo., Oct. 29, 2020 (GLOBE NEWSWIRE) — Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on
Read moreBrickell Biotech Announces Pricing of $15.0 Million Underwritten Public Offering
BOULDER, Colo., Oct. 22, 2020 (GLOBE NEWSWIRE) — Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on
Read moreBrickell Biotech Announces Approval of Sofpironium Bromide Gel, 5% in Japan for Treatment of Primary Axillary Hyperhidrosis Received by its Development Partner, Kaken Pharmaceutical
Japan is the first country to approve sofpironium bromide with commercial launch expected later this year Brickell is on track
Read moreBrickell Biotech to Participate in September Virtual Investor Conferences
BOULDER, Colo., Sept. 10, 2020 (GLOBE NEWSWIRE) — Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on
Read moreBrickell Biotech Announces Issuance of New Composition of Matter Patent on Sofpironium Bromide by the Japanese Patent Office
Claims directed to novel crystalline forms of sofpironium bromide Patent protection in Japan granted through 2040 BOULDER, Colo., Aug. 31,
Read moreBrickell Biotech Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Positive data from the Sofpironium Bromide Phase 3 pivotal study in Japan presented in Q2 2020 by development partner, Kaken
Read moreBrickell Biotech to Report Second Quarter 2020 Financial Results and Provide a Corporate Update on August 12, 2020
BOULDER, Colo., Aug. 03, 2020 (GLOBE NEWSWIRE) — Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on
Read moreBrickell Biotech, Inc. Announces Pricing of $20.1 Million Underwritten Public Offering
BOULDER, Colo., June 17, 2020 (GLOBE NEWSWIRE) — Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on
Read more